Effect of Anti-diabetic Drugs on Glycemic Variability

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.

Also called NCT02925559

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 135 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as a collaborator
Registry
  • NCT NCT02925559
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02925559. Randomized; no masking; primary purpose treatment. Start 2016-10 (actual); primary completion 2018-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Anti-diabetic Drugs on Glycemic Variability
Acronym
EFFORT
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Gliclazide MR
Lead sponsor
Centro de Diabetes Curitiba Ltda (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02925559
Content hash
228e9af975eb82a9b4ed2ea1dbf72b2b41c69217e6ce2dbe7d5556022146001c